Who was studied?
One patient with pMMR metastatic gastric adenocarcinoma and limited tolerance of intensive treatment.
What does the publication report?
The report described a complete response and 14 months of progression-free survival, with improved performance status.
Safety findings
The abstract does not present a complete graded safety profile.
How should we interpret it?
A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report · DOI: 10.3389/fimmu.2022.926740 · PMID: 35874658
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.